GlassScriptPhysician profile
Ricardo Ruiz
NPI 1790989036
$942.28
in general payments reported to CMS, 2019-2025
10 companies · $88.18 in 2025
The $88.18 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2021: $278 · 2022: $243 · 2023: $41.78 · 2024: $54.36 · 2025: $88.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $184.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $288.17 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $95.91 | 2022 | |
| Janssen Pharmaceuticals, INC | $91.69 | 2021 | |
| Sanofi-Aventis U.S. LLC | $91.39 | 2019-2021 | |
| Dexcom, INC. | $88.18 | 2025 | Dexcom G6 Transmitter |
| Pbg Puerto Rico LLC | $88.12 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $82.70 | 2019 | |
| Lilly USA, LLC | $54.36 | 2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Ruiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.